TABLE 2.

Summary of population pharmacokinetic analysis for cefazolin

Models	OBJa	−2.l.l.db	P value
Basic modelc (2-compartment model)d	2165.442
CL
θ1 × (CLcr/CLcr median)θ5	2,150.072	15.37	<0.01
θ1 (age > 65), θ5 (age ≦ 65)	2,165.094	0.348	NS
θ1 (sex = male), θ5 (sex = female)	2,165.374	0.068	NS
Vc
θ1 + θ5 × BW	2,155.392	10.05	<0.01
Q
θ1 × (CLcr/CLcr median)θ5	2,163.986	1.456	NS
θ1 (age > 65), θ5 (age ≦ 65)	2,164.271	1.171	NS
θ1 (sex = male), θ5 (sex = female)	2,165.339	0.103	NS
VJC
θ1 + θ5 × BW	2,150.933	14.449	<0.01

^aOBJ, objective function.

^b–2 log-likelihood.

^cCL, clearance; V_c, volume of distribution of the central compartment; Q, central hip joint capsule compartment clearance; V_JC, volume of distribution of the hip joint capsule compartment; NS, not significant.

^dCL (liters/h) = θ1, V_c (liters) = θ2, Q (liters/h) = θ3, V_JC (liters) = θ4.